Loading...
XSTOSDOS
Market cap8mUSD
Dec 23, Last price  
1.64SEK
1D
2.50%
1Q
-2.38%
Jan 2017
-64.88%
IPO
-87.99%
Name

ScandiDos AB

Chart & Performance

D1W1MN
XSTO:SDOS chart
P/E
—
P/S
1.55
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.57%
Rev. gr., 5y
4.36%
Revenues
60m
-1.82%
28,933,00035,979,00039,834,00038,699,00032,923,00033,576,00047,408,00050,570,00048,824,00057,271,00059,990,00057,684,00061,550,00060,429,000
Net income
-15m
L+60.62%
321,000227,000-2,093,000-4,200,000-14,683,000-14,242,000-13,157,000-11,565,000-17,761,000-13,134,000-1,399,000-7,338,000-9,119,000-14,647,000
CFO
1m
P
2,311,000-4,437,000-10,779,000-18,559,000-13,168,000-9,167,000-13,315,000-5,664,0008,638,0002,391,000-11,902,0001,485,000
Earnings
Mar 12, 2025

Profile

ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose verification covering various treatment technologies, such as VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy; Delta4 Discover, a transmission detector that provides confidence and patient safety based on real time measurements; and Delta4 Phantom+, a system that offers accurate and verification of IMRT, VMAT, and TomoTherapy plans. It also provides HexaMotion, a motion management solution; Delta4DVH Anatomy, a software that verifies and analyzes the dose delivered in the patient anatomy; and Delta4 Machine QA, a software to perform QA with respect to rotation, start-up behavior, and dynamic beam modulation. The company was founded in 2005 and is headquartered in Uppsala, Sweden.
URL
https://scandidos.com/
IPO date
Apr 11, 2014
Employees
31
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑042015‑04
Income
Revenues
60,429
-1.82%
61,550
6.70%
57,684
-3.84%
Cost of revenue
15,123
13,864
30,446
Unusual Expense (Income)
NOPBT
45,306
47,686
27,238
NOPBT Margin
74.97%
77.48%
47.22%
Operating Taxes
(98)
446
Tax Rate
1.64%
NOPAT
45,306
47,784
26,792
Net income
(14,647)
60.62%
(9,119)
24.27%
(7,338)
424.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,450
BB yield
-12.64%
Debt
Debt current
(10,946)
(8,330)
Long-term debt
Deferred revenue
Other long-term liabilities
3,282
737
Net debt
(1,531)
(14,975)
(15,094)
Cash flow
Cash from operating activities
1,485
(11,902)
2,391
CAPEX
(4,407)
(4,706)
Cash from investing activities
(2,943)
(4,367)
(4,766)
Cash from financing activities
12,333
(83)
FCF
26,042
47,117
42,996
Balance
Cash
1,531
3,546
6,241
Long term investments
483
523
Excess cash
952
3,880
Stockholders' equity
(116,994)
(119,627)
(86,617)
Invested Capital
164,563
151,068
115,485
ROIC
28.71%
35.85%
22.38%
ROCE
95.24%
151.67%
94.35%
EV
Common stock shares outstanding
45,609
45,609
41,459
Price
1.72
-20.37%
2.16
-2.26%
2.21
-49.20%
Market cap
78,447
-20.37%
98,515
7.52%
91,624
-49.20%
EV
76,916
83,540
76,530
EBITDA
47,622
53,012
31,817
EV/EBITDA
1.62
1.58
2.41
Interest
1,156
793
165
Interest/NOPBT
2.55%
1.66%
0.61%